Article

After Patient Death, FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Trial

2022-02-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7c9435c3-9d70-58d3-9668-ca7057d9f888
DOI: 10.1089/hum.2022.29198.bfs

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

After Patient Death, FDA Places Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy TrialDOI 10.1089/hum.2022.29198.bfsRead

Food and Drug Administration Lifts Clinical Hold on Pfizer Duchenne Muscular Dystrophy Gene Therapy Linked to Patient DeathSemantic proximity Read

Meeting Report: 2022 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Transfer Therapy’Semantic proximity Read

Meeting Report: 2023 Muscular Dystrophy Association Summit on ‘Safety and Challenges in Gene Therapy of Neuromuscular Diseases’Semantic proximity Read

Consensus recommendations and considerations for the delivery and monitoring of gene therapy in patients with Duchenne muscular dystrophySemantic proximity Read

Gene therapy enters the pharma market: the short story of a long journey.Semantic proximity Read

Long-term follow-up after authorization of gene therapy: leveraging real-world dataSemantic proximity Read

Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular DystrophySemantic proximity Read

Delandistrogene Moxeparvovec Gene Therapy in Individuals With Duchenne Muscular Dystrophy: Evidence in FocusSemantic proximity Read

Access to gene therapy for rare diseases when commercialization is not fit for purposeSemantic proximity Read

Practical Considerations for Delandistrogene Moxeparvovec Gene Therapy in Patients With Duchenne Muscular DystrophySemantic proximity Read

Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular DystrophySemantic proximity Read

From Bench to Bedside: A Meta-Analysis of Translational Research in Duchenne Muscular DystrophySemantic proximity Read